DARPins as Entry Inhibitor Alternative to HIV-1 Broadly Neutralizing Antibodies
Background: Development of drugs that share the properties of broadly neutralizing antibodies (BNAbs) is highly desirable. Here we utilize the Designed Ankyrin Repeat Protein (DARPin) technology to generate HIV-1 inhibitors with broad neutralization activity directed against the V3 loop. DARPins, small synthetic binding proteins with high target affinities and specificities, have interesting properties as anti-HIV…